Elemer Piros
Stock Analyst at Rodman & Renshaw
(3.25)
# 1,061
Out of 4,761 analysts
109
Total ratings
36.89%
Success rate
5.86%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FBLG FibroBiologics | Initiates: Buy | $12 | $1.13 | +966.67% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $1.90 | +794.74% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.40 | +685.71% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $40.25 | +24.22% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.10 | +1,445.45% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $22 | $0.43 | +4,967.96% | 1 | Aug 19, 2024 | |
| SAVA Cassava Sciences | Reiterates: Buy | $107 | $2.55 | +4,096.08% | 1 | Aug 8, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $0.58 | +2,300.55% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $2.13 | +3,045.54% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $43 | $3.19 | +1,247.96% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.41 | +180.81% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.06 | +607.55% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.99 | +653.77% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $7.63 | +175.23% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $4.21 | +802.61% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $1.30 | +2,976.92% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.62 | +710.50% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $9.09 | +1,154.13% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $4.43 | +4,414.67% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $5.02 | +358.17% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $12.51 | +163.79% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $27.52 | +45.35% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $40 | $1.94 | +1,961.86% | 3 | Jan 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.80 | +1,955.56% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $6.51 | +391.55% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $17.77 | +333.31% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.80 | +8,660.95% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.18 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $19.90 | +151.26% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $6.69 | +393.27% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $13.33 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $9.18 | +183.22% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $187.86 | -85.10% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.78 | +14,605.88% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $7.00 | +200.00% | 2 | Jul 12, 2017 |
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $1.13
Upside: +966.67%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $1.90
Upside: +794.74%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.40
Upside: +685.71%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $40.25
Upside: +24.22%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.10
Upside: +1,445.45%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $22
Current: $0.43
Upside: +4,967.96%
Cassava Sciences
Aug 8, 2024
Reiterates: Buy
Price Target: $107
Current: $2.55
Upside: +4,096.08%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $0.58
Upside: +2,300.55%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $2.13
Upside: +3,045.54%
Alto Neuroscience
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $3.19
Upside: +1,247.96%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $6.41
Upside: +180.81%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.06
Upside: +607.55%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $1.99
Upside: +653.77%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $7.63
Upside: +175.23%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $4.21
Upside: +802.61%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $1.30
Upside: +2,976.92%
Jun 30, 2023
Reiterates: Buy
Price Target: $5
Current: $0.62
Upside: +710.50%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $9.09
Upside: +1,154.13%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $4.43
Upside: +4,414.67%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $5.02
Upside: +358.17%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $12.51
Upside: +163.79%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $27.52
Upside: +45.35%
Jan 4, 2022
Upgrades: Buy
Price Target: $40
Current: $1.94
Upside: +1,961.86%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.80
Upside: +1,955.56%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $6.51
Upside: +391.55%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $17.77
Upside: +333.31%
Oct 12, 2020
Initiates: Buy
Price Target: $70
Current: $0.80
Upside: +8,660.95%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.18
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $19.90
Upside: +151.26%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $6.69
Upside: +393.27%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $13.33
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $9.18
Upside: +183.22%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $187.86
Upside: -85.10%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.78
Upside: +14,605.88%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $7.00
Upside: +200.00%